Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Cambridgeshire based Director operating in the Medical space. If you think a Director is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Vincenzo Garzya
Patient Centricity Excellence Director of AstraZeneca
Follow Vincenzo Garzya:
About AstraZeneca: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
Claus Bendtsen
Executive Director of AstraZeneca
Claus Bendtsen heads Quantitative Biology as part of Discovery Sciences within AstraZeneca. His department provides global support in areas of informatics, mathematical modelling, image analytics and non-clinical statistics. Prior to joining AstraZeneca he held positions at Novartis and Merck & Co. Earlier in his career he co-founded three start-ups and worked in academia. He holds a Ph.D. in applied mathematics and an MBA.
Follow Claus Bendtsen:
About AstraZeneca: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
Ilaria Grizzi
Director, System Integration of Illumina
Follow Ilaria Grizzi:
About Illumina: Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
Richard Durbin
Informatics Director of Congenica
Richard is a Group Leader of the Human Genetics Programme at the Wellcome Trust Sanger Institute, a Fellow of the Royal Society, and a Member of EMBO. A pioneer in the industry, he has developed sequence data analysis tools that are now standards in the field. His current research focuses on human genetic variation by large scale genome-wide re-sequencing. Richard has led the international 1000 Genomes Project and the UK10K Genome Project, and has made significant contributions to the Ensembl resource for vertebrate genome annotation, and the TreeFam and Pfam databases.
Follow Richard Durbin:
About Congenica: Congenica is a biotechnology company that provides a diagnostic decision support platform.
Matthew Hurles
Scientific Director of Congenica
Matt is Senior Group Leader at the Wellcome Trust Sanger Institute and a leader in the Deciphering Developmental Disorders, 1000 Genomes and UK10K projects. He has pioneered the analysis of whole exomes in clinically relevant disorders that previously failed diagnostic methods, and has led an initiative to characterise structural variation in the human genome, and integrate this knowledge into disease and population genetic studies. Matt has been awarded the Balfour Lecture by the Genetics Society and the Crick Lecture prize for accomplishments in genetics by the Royal Society.
Follow Matthew Hurles:
About Congenica: Congenica is a biotechnology company that provides a diagnostic decision support platform.
Luke Hares
Technology Director of CMR Surgical
Before co-founding CMR he worked for product design companies in the UK and the US, where he worked on medical devices, robotics, ASIC developments and consumer products. Luke believes the best devices are created by combining a detailed knowledge of the unmet needs of the users with the creative application of a broad knowledge of available technology. Regular contact and interaction with the users of the product is essential for this process. Luke is responsible for leading the CMR technology team and has overall responsiblilty for the technology strategy of the company. He is accustomed to championing ideas, communicating technically complex ideas and designing and managing the development of complex systems.
Follow Luke Hares:
About CMR Surgical: CMR Surgical is developing the next-generation surgical robotic system for minimal access surgery.
Shankar Balasubramian
Co-Founder and Director of Cambridge Epigenetix
Sir Shankar is Founder of two companies and the principal inventor of the leading next generation human genome sequencing technology core to all Illumina sequencing platforms, estimated to be worth >$30BN. Sir Shankar’s technology has made routine, accurate, low-cost sequencing of human genomes a reality, has revolutionised biology and accelerated the development of genomic personalised medicine. Sir Shankar is the Herchel Smith Professor of Medicinal Chemistry at the University of Cambridge and Senior Group Leader at the Cancer Research UK Cambridge Institute. His awards include the Royal Medal (2018), the RoyalSociety Mullard Award (2009), The BBSRC Innovator of the year (2010) and the Tetrahedron Prize (2013). He is a Fellow of the Royal Society, the Academy of Medical Sciences and a member of EMBO.
Follow Shankar Balasubramian:
About Ahren Innovation Capital, Cambridge Epigenetix: Cambridge Epigenetix is using epigenetics to reduce several routine & important diagnostic tests for common cancers to a simple blood draw.
Martin Murphy
Associate Director of Cambridge Epigenetix
Follow Martin Murphy:
About Cambridge Epigenetix: Cambridge Epigenetix is using epigenetics to reduce several routine & important diagnostic tests for common cancers to a simple blood draw.
Anya Roy
Managing Director of Syrona Health
Anya Roy is the co-founder of Syrona Health.
Follow Anya Roy:
About Syrona Health: Syrona Health is a personalised digital health platform for Chronic Gynaecological/Uterine Conditions like Endometriosis, PCOS etc.
Oriane Chausiaux
Founder Director – CSO, Serial Entrepreneur of Heartfelt Technologies
Follow Oriane Chausiaux:
About Heartfelt Technologies: Heartfelt Technologies are developing the only home-based heart failure monitor that does not require patient interaction or compliance.
Paul Bailey
Non-Executive Director of Bailey Fisher Executive Search
Paul co-founded Bailey Fisher Executive Search in 1998 and led the growth of the business as Managing Director for 20 years during which time he built the board and management teams for some of the most innovative companies to have emerged from the European technology market. After a successful exit in July 2018, he took on the role of Executive Chairman. Paul was named in the 2016 Maserati 100 and was recognised as one of the most influential business people in Cambridge in 2017. He has held advisory roles with NESTA Impact Investments and New Wave Ventures. Paul joined Martlet Capital in 2019. He is also currently Entrepreneur in Residence at Cambridge Enterprise.
Follow Paul Bailey:
About : Bailey Fisher is an independent executive search firm finding & attracting individuals who have a fundamental impact on business growth.
Kate Hudson-Farmer
Director, Front-End Innovation, Drug Delivery of Medicom Innovation Partner
Kate Hudson-Farmer is Director, Front-End Innovation and Drug Delivery at Medicom Innovation Partner.
Follow Kate Hudson-Farmer:
About Medicom Innovation Partner: Medicom Innovation Partner is a provider of device strategy, product design and development services.
Andrew Southan
Chief Executive and Executive Director of Metrion Biosciences
Andy has over 25 years’ experience in life science research, including 14 years in the CRO sector. In 1991 he received his PhD in Pharmacology from the University of London (UK), investigating the effects of anaesthetics and high pressure on CNS potassium channels. Following a move to industry Andy worked as a brain slice electrophysiologist supporting ion channel-based CNS programmes at Wyeth (UK), before moving to Imperial College London where he published the first patch-clamp recordings from cerebellar inhibitory nerve terminals. At CeNeS Pharmaceuticals he performed CRO services (hERG, nAChR) and internal research on HCN and two-pore channels. He subsequently established the electrophysiology laboratory for Ionix Pharmaceuticals, a company focused on identifying novel pain therapeutics, where he worked on Nav, Cav and mechanosenstive ion channels. Before joining Metrion Andy spent 12 years in leadership roles at BioFocus and Charles River managing stand-alone projects, multi-year collaborations and fully integrated drug discovery programmes.
Follow Andrew Southan:
About Metrion Biosciences: Metrion Biosciences is a Contract Research Organization (CRO) that is located in the world renowned Cambridge biocluster.
